Nippon India Pharma Fund in brief
Nippon India Pharma Fund is a sectoral and thematic fund from Nippon India Mutual Fund, one of 226 sectoral and thematic funds with a year or more of history. As of 20 Nov 2026, its direct plan returned 15.4% a year over 5 years. The regular plan returned 14.4% a year, 1.03% less. The fund manages about ₹9,087 crore and its direct plan charges 0.99% a year. Measured from every starting month since November 2016, its three year returns ranged from 2.6% to 30.5% a year, and none lost money. Its deepest fall in the last five years was 18.7%, in June 2022. Of the similar funds checked, it shares the most with Aditya Birla Sun Life Manufacturing Equity Fund: 10% of the portfolio.
Returns
Growth option. Annualised, to 20 Nov 2026.
| 1 year | 3 years | 5 years | |
|---|---|---|---|
| Direct plan | 15.3% | 18.0% | 15.4% |
| Regular plan | 14.3% | 16.9% | 14.4% |
Nippon India Pharma Fund Direct Growth NAV on 20 Nov 2026: ₹666.342. Regular Growth NAV: ₹591.2429. A fund's NAV already has its costs taken out, so these are the returns an investor received, before tax.
Nippon India Pharma Fund is a sectoral and thematic fund.
Direct plan against regular plan
Both plans hold the same portfolio. Over 5 years, the direct plan returned 15.4% a year and the regular plan 14.4%. The difference of 1.03% a year is mostly the commission the regular plan pays a distributor.
See what that costs over timeWhy there is no ranking here
Sector and theme funds are not ranked against each other here, because each follows a different slice of the market. A sector or theme fund is a bet on one part of the economy. Look at how large a part of your portfolio it is, and what would have to go right for it to pay off.
Check your whole portfolio
One fund says little on its own. Add everything you hold to see what you pay in commissions, which funds double up and where the portfolio is lopsided.
Check your portfolioTalk it through first
Whether a fund belongs in your portfolio depends on your goals, your tax position and what else you own. An advisor will go through it with you on a free call.
Talk to an advisorHow steady Nippon India Pharma Fund has been
A single return depends on when you start counting. These figures look at every starting month instead, and at the worst stretch an investor sat through. Worked out from the fund's daily NAVs, direct plan.
Three year returns, from every start
Of the 85 three year periods starting each month since November 2016, the worst returned 2.6% a year, the middle one 21.1% and the best 30.5%. None of them lost money.
Ups and downs
Over the last three years, its monthly returns had a volatility (annualised standard deviation) of 14.1%. Its deepest fall from a peak in the last five years was 18.7%, bottoming in June 2022. It has since climbed back above that peak.
Top holdings of Nippon India Pharma Fund
The ten largest of its 37 shares, as the fund last disclosed them. Together they are 57% of the fund.
| Company | Sector | Part of the fund |
|---|---|---|
| Sun Pharma.Inds. | Pharmaceuticals | 11.6% |
| Divi's Lab. | Pharmaceuticals | 6.7% |
| Cipla | Pharmaceuticals | 6.2% |
| Lupin | Pharmaceuticals | 6.2% |
| Dr Reddy's Labs | Pharmaceuticals | 6.1% |
| Apollo Hospitals | Healthcare | 5.1% |
| Mankind Pharma | Pharmaceuticals | 4.4% |
| Sai Life | Pharmaceuticals | 4.0% |
| Ajanta Pharma | Pharmaceuticals | 3.5% |
| Max Healthcare | Healthcare | 3.3% |
Largest sectors
Where the fund's equity money sits.
Holdings change every month. If you hold more than one fund, the portfolio check shows how much of the same shares they hold.
How much Nippon India Pharma Fund shares with similar funds
The overlap is the part of the portfolio two funds hold in common, share by share, from their last disclosed holdings. A high overlap means owning both adds little.
Other sectoral and thematic funds
The 226 funds in this category with at least a year behind them. See their returns side by side.
Questions
What is the return of Nippon India Pharma Fund?
As of 20 Nov 2026, the direct plan of Nippon India Pharma Fund returned 15.3% over 1 year, 18.0% a year over 3 years, 15.4% a year over 5 years. The regular plan returned 14.4% a year over 5 years. Returns over more than a year are annualised.
What is the NAV of Nippon India Pharma Fund Direct Growth?
Nippon India Pharma Fund Direct Growth NAV on 20 Nov 2026: ₹666.342. Regular Growth NAV: ₹591.2429. NAVs are published by AMFI at the end of each business day.
What is the difference between the direct and regular plan of Nippon India Pharma Fund?
They hold the same portfolio, run by the same manager. The regular plan pays a commission to a distributor each year, so it returned 1.03% a year less over 5 years.
What is the expense ratio of Nippon India Pharma Fund?
The direct plan of Nippon India Pharma Fund charges 0.99% a year, and the fund manages about ₹9,087 crore. The regular plan charges more, to pay the distributor's commission. Expense ratios change, so check the fund's latest factsheet.
What are the top holdings of Nippon India Pharma Fund?
As last disclosed, its largest holdings are Sun Pharma.Inds. (11.6%), Divi's Lab. (6.7%), Cipla (6.2%), Lupin (6.2%), Dr Reddy's Labs (6.1%). The ten largest make up 57% of the fund, which holds 37 shares in all.
How risky has Nippon India Pharma Fund been?
Its monthly returns over the last three years had an annualised volatility of 14.1%. Measured from every starting month since November 2016, its three year returns ranged from 2.6% to 30.5% a year, and none lost money. Its deepest fall in the last five years was 18.7%, in June 2022.
Why is Nippon India Pharma Fund not ranked?
Sector and theme funds are not ranked against each other here, because each follows a different slice of the market. A sector or theme fund is a bet on one part of the economy. Look at how large a part of your portfolio it is, and what would have to go right for it to pay off.
This page is information, not a recommendation to buy, sell or hold any fund. Returns are annualised, for the growth option, from NAVs published by AMFI. A ranking by past return says nothing certain about the future, and the right fund for you depends on your goals and the rest of your portfolio.
Invsify Technologies Private Limited is a SEBI Registered Investment Adviser, Registration No. INA000020572. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Past performance is not indicative of future results.